Behavioural effects of co-administration of delta9-tetrahydrocannabinol with fluoxetine in rats.
Matthew Goddard, Paul F Smith, John C Ashton
Study at a glance
AI-extracted from the abstract| Characteristics | Controlled experimental animal study Peer reviewed |
|---|---|
| Population | Rats |
| Interventions | Fluoxetine hydrochloride delta9-tetrahydrocannabinol |
| Topics | Cannabis |
| Key findings | Coadministering fluoxetine and delta9-tetrahydrocannabinol to rats did not potentiate or reduce the behavioural effects of either drug alone, contrary to the hypothesis that SSRIs increase cannabinoid-induced panic. Fluoxetine did not alter freezing, social interaction, exploration, zone preference, or rearing in THC-treated rats. |
Abstract
Previous studies have suggested panic induced by cannabinoids may be potentiated by concurrently using selective serotonin reuptake inhibitors. We therefore tested for panic and anxiety-related behaviour in rats coadministered with the selective serotonin reuptake inhibitor fluoxetine hydrochloride and the CB1 agonist delta9-tetrahydrocannabinol. Although each drug alone elicited behaviours consistent with previous studies, we did not find that coadministration of these drugs potentiated or reduced the effects of either drug alone. Specifically, fluoxetine treatment did not cause any increase in freezing behaviour, decrease in social interaction or exploration in an adverse environment, change preference for outer or inner zones, or modulate rearing behaviour in rats receiving delta9-tetrahydrocannabinol.
Comparable studies
Other preclinical and animal studies on cannabis, most cited first.